Apellis Pharmaceuticals Inc (NASDAQ:APLS) major shareholder Morningside Venture Investment acquired 441,176 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was purchased at an average cost of $17.00 per share, with a total value of $7,499,992.00. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Shares of NASDAQ APLS opened at $19.33 on Friday. Apellis Pharmaceuticals Inc has a 52 week low of $11.45 and a 52 week high of $32.00. The company has a quick ratio of 11.89, a current ratio of 11.89 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -5.25 and a beta of 0.37.
Hedge funds and other institutional investors have recently modified their holdings of the business. Flinton Capital Management LLC bought a new position in Apellis Pharmaceuticals in the 4th quarter worth about $36,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Apellis Pharmaceuticals by 159.7% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,903 shares of the company’s stock worth $38,000 after purchasing an additional 1,785 shares during the period. Great West Life Assurance Co. Can bought a new position in Apellis Pharmaceuticals in the 3rd quarter worth about $107,000. PNC Financial Services Group Inc. boosted its stake in Apellis Pharmaceuticals by 35.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,380 shares of the company’s stock worth $124,000 after purchasing an additional 2,440 shares during the period. Finally, Metropolitan Life Insurance Co. NY boosted its stake in Apellis Pharmaceuticals by 356.7% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 12,216 shares of the company’s stock worth $161,000 after purchasing an additional 9,541 shares during the period. Institutional investors and hedge funds own 53.89% of the company’s stock.
APLS has been the subject of several recent research reports. Zacks Investment Research lowered Apellis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 16th. Cantor Fitzgerald set a $53.00 price objective on Apellis Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, December 3rd. Citigroup lifted their price objective on Apellis Pharmaceuticals from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, December 6th. B. Riley initiated coverage on Apellis Pharmaceuticals in a report on Tuesday, January 8th. They issued a “buy” rating and a $40.00 price objective for the company. Finally, JPMorgan Chase & Co. lowered Apellis Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $34.00 price objective for the company. in a report on Wednesday, January 23rd. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $39.33.
WARNING: This report was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2019/03/15/insider-buying-apellis-pharmaceuticals-inc-apls-major-shareholder-buys-441176-shares-of-stock.html.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
See Also: What is a Swap?
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.